Drug approval: Crizotinib in unresectable or refractory ALK-positive pediatric inflammatory myofibroblastic tumors

被引：0
|
作者：
Tenaillon, Anne [1 ]
Orbach, Daniel [1 ]
机构：
[1] Inst Curie, Ctr Integre Soins & Rech Oncol Enfant Adolescent &, 26 rue Ulm, F-75005 Paris, France
来源：
BULLETIN DU CANCER | 2023年 / 110卷 / 04期
关键词：
Inflammatory myofibroblastic tumor; Targeted therapy; ALK-positive; Crizotinib; Children;
D O I：
10.1016/j.bulcan.2022.12.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：248 / 249
页数：2
相关论文
共 50 条
  • [31] Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Thibault, Constance
    Teixeira, Luis
    ONCOLOGIE, 2013, 15 (09) : 494 - 495
  • [32] Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib
    Gambacorti-Passerini, Carlo
    Mussolin, Lara
    Brugieres, Laurence
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (01): : 95 - 96
  • [33] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [34] Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma
    Zito Marino, Federica
    Morabito, Alessandro
    Gridelli, Cesare
    Rocco, Gaetano
    Liguori, Giuseppina
    De Rosa, Nicla
    Botti, Gerardo
    Franco, Renato
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2016, 24 (09) : E86 - E88
  • [35] First-Line Crizotinib in ALK-Positive Lung Cancer
    Tural, Deniz
    Kilickap, Saadettin
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 781 - 781
  • [36] Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
    Camidge, D. Ross
    Kim, Elizabeth E.
    Usari, Tiziana
    Polli, Anna
    Lewis, Iona
    Wilner, Keith D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1077 - 1085
  • [37] Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with ALK Gene Rearrangements and Response to Crizotinib
    Rakheja, Dinesh
    Park, Jason Y.
    Fernandes, Neil J.
    Watt, Tanya C.
    Laetsch, Theodore W.
    Collins, Rebecca R. J.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2022, 30 (06) : 706 - 715
  • [38] Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement
    Rafee, Shereen
    Elamin, Yasir Y.
    Joyce, Eimear
    Toner, Mary
    Flavin, Richard
    McDermott, Ronan
    Sheehy, Niall
    Hennessy, Bryan
    O'Byrne, Kenneth
    Gleeson, Noreen
    Osman, Nemer
    TUMORI, 2015, 101 (02) : E35 - E39
  • [39] How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature
    Alan, Ozkan
    Kuzhan, Okan
    Koca, Sinan
    Telli, Tugba Akin
    Tuylu, Tugba Basoglu
    Ercelep, Ozlem
    Filinte, Deniz
    Sengul, Yildiz
    Arikan, Huseyin
    Kaya, Serap
    Babacan, Nalan Akgul
    Dane, Faysal
    Yumuk, Perran Fulden
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 1011 - 1018
  • [40] Differential crizotinib response duration among ALK fusion variants in ALK-positive NSCLC
    Yoshida, T.
    Oya, Y.
    Tanaka, K.
    Shimizu, J.
    Horio, Y.
    Hida, T.
    Yatabe, Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 139 - 139
12345